Background
Elevated resting heart rate is a risk factor for cardiovascular events.
Objective
The purpose of this study was to investigate the clinical significance of nocturnal
heart rate (nHR) and 24-hour mean heart rate (24h-HR) obtained by continuous remote
monitoring (RM) of implantable devices.
Methods
We analyzed daily-sampled trends of nHR, 24h-HR, and physical activity in patients
on β-blocker therapy for chronic heart failure and with implantable cardioverter-defibrillators
or cardiac resynchronization therapy defibrillators (CRT-Ds). Patients were grouped
by average nHR and 24h-HR quartile during follow-up to estimate the respective incidence
of nonarrhythmic death and device-treated ventricular tachycardia/fibrillation (VT/VF).
Results
The study cohort included 1303 patients (median age 69 years [interquartile range
61–77 years]; 41% with CRT-D; median follow-up 25 months [interquartile range 13–42
months]). Compared with patients in the lowest nHR quartile (≤57 beats/min) group,
patients in the highest quartile group (>65 beats/min) had an increased risk of nonarrhythmic
death (adjusted hazard ratio [AHR] 2.25; 95% confidence interval [CI] 1.13–4.50; P = .021) and VT/VF (AHR 1.98; 95% CI 1.40–2.79; P < .001) and were characterized by the lowest level of physical activity (P ≤ .0004 vs every other nHR quartiles). The highest 24h-HR quartile group (>75 beats/min)
showed an increased risk of VT/VF (AHR 2.13; 95% CI 1.52–2.99; P < .001) and a weaker though significant association with nonarrhythmic mortality
(AHR 1.80; 95% CI 1.00–3.22; P = .05) as compared with the lowest 24h-HR quartile group (≤65 beats/min).
Conclusion
In remotely monitored implantable cardioverter-defibrillator/CRT-D patients on β-blocker
therapy for heart failure, elevated heart rates (nHR >65 beats/min and 24h-HR >75
beats/min) were associated with increased mortality and VT/VF risk. nHR showed a stronger
association than 24h-HR with worst prognosis and lowest physical activity.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart rate and cardiovascular mortality: the Framingham Study.Am Heart J. 1987; 113: 1489-1494
- on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.Lancet. 2008; 372: 817-821
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet. 2010; 376: 886-894
- Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure.Int J Cardiol. 2018; 253: 97-104
- Heart rate in patients with reduced ejection fraction: relationship between single time point measurement and mean heart rate on prolonged implantable cardioverter defibrillator monitoring.BMC Cardiovasc Disord. 2018; 18: 17
- Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: a survey from the Home Monitoring Expert Alliance project.Clin Cardiol. 2019; 42: 76-83
- Elevated heart rate: a major risk factor for cardiovascular disease.Clin Exp Hypertens. 2004; 26: 637-644
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2022; 79: e263-e421
- Resting heart rate as a predictive risk factor for sudden death in middle-aged men.Cardiovasc Res. 2001; 50: 373-378
- for the Heart Rate Working Group. Resting heart rate in cardiovascular disease.J Am Coll Cardiol. 2007; 50: 823-830
- Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.J Am Coll Cardiol. 2012; 59: 1785-1795
- Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.Eur Heart J. 2015; 36: 669-675
- Heart rate predicts outcomes in an implantable cardioverter-defibrillator population.Circulation. 2009; 120: 2040-2045
- Patient activity and survival following implantable cardioverter-defibrillator implantation: the ALTITUDE activity study.J Am Heart Assoc. 2015; 4e001775
- Association of implantable device measured physical activity with hospitalization for heart failure.JACC Heart Fail. 2020; 8: 280-288
- Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.Europace. 2022; 24: 234-244
- Relation between resting heart rate and the risk of ventricular tachyarrhythmias in MADIT-RIT.Europace. 2020; 22: 281-287
- Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis.Heart Rhythm. 2010; 7: 1900-1906
- Survival after implantable cardioverter-defibrillator shocks.J Am Coll Cardiol. 2021; 77: 2453-2462
- Influence of “high” defibrillation thresholds on patient survival and impact of system modification.J Cardiovasc Electrophysiol. 2022; 33: 234-240
- Lower rate limit for pacing by cardiac resynchronization defibrillators: should lower rate programming be reconsidered?.Heart Rhythm. 2021; 18: 2087-2093
- The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: results from the THINGS registry.J Cardiovasc Electrophysiol. 2020; 31: 846-853
- Less is more: can we achieve cardiac resynchronization with 2 leads only?.Int J Cardiol. 2017; 249: 184-190
- Rate-responsive pacing and atrial high rate episodes in cardiac resynchronization therapy patients: is low heart rate the key?.Clin Cardiol. 2019; 42: 820-828
Article Info
Publication History
Published online: October 27, 2022
Publication stage
In Press Journal Pre-ProofFootnotes
Funding Sources: Manuscript editing was partially supported by Biotronik Italia S.p.A. (Via Alessandro Volta 16, 20093, Cologno Monzese (MI), Italy). No other funds have been received to support this work.
Disclosures: Mr Giacopelli and Mr Gargaro are employees of Biotronik Italia.
Identification
Copyright
© 2022 Heart Rhythm Society. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Role of remote monitoring–derived heart rates in the risk stratification of heart failure with reduced ejection fraction: New insightsHeart Rhythm
- PreviewIn BC 2600, Gilgamesh, the king of the Mesopotamian Epic of Gilgamesh, lamented the death of his best friend and recorded the passage “I touch his heart but it does not beat at all.”1 This passage was felt to be the earliest reference of a pulse, and it reflected intimate knowledge of the heartbeat and mortality.
- Full-Text
- Preview
